Tumor Mutational Burden as a Biomarker of Immunotherapy Response: An Immunogram Approach in Onco-immunology

Title:Tumor Mutational Burden as a Biomarker of Immunotherapy Response: An Immunogram Approach in Onco-immunology

Volume: 24

Author(s): Afzal Ansari, Suman Kumar Ray, Mukul Sharma, Rakesh Rawal and Pushpendra Singh*

Affiliation:

• ICMR-National Institute of Research in Tribal Health, Jabalpur, MP, India

Abstract: Immune checkpoint inhibitors have revolutionized cancer treatment by allowing T cells to reactivate. Tumor mutational burden (TMB) is a biomarker that has emerged as a viable diagnostic for locating patients who would benefit from immunotherapy in particular cancer types. Greater neo-antigens mean more opportunities for T cell identification, and TMB is clinically linked to better immune checkpoint inhibitors. Tumor foreignness is a cancer immunogram, and TMB can be used as a substitute for foreignness. The role of TMB analysis as an independent predictor of immunotherapy response in the context of immune checkpoint inhibitor medications is the subject of this mini-review.

Cite this article as:

Ansari Afzal, Ray Suman Kumar, Sharma Mukul, Rawal Rakesh and Singh Pushpendra*, Tumor Mutational Burden as a Biomarker of Immunotherapy Response: An Immunogram Approach in Onco-immunology, Current Molecular Medicine 2024; 24 () . https://dx.doi.org/10.2174/0115665240266906231024111920